Pyxis Oncology, Inc.
NASDAQ:PYXSBiotechnology
Healthcare
$1.41 +5.53%
+$0.11 today
- Market cap
- $168.65M
- Beta
- 1.43
- P/E (TTM)
- -1.6
- EPS (TTM)
- -$1.29
52W Low $0.97High $5.55
Volume 0.75M
Average 0.50M
Income Statement
Follow revenue through to earnings.
Revenue
$13.86M
FY 2025 · Annual
-14.2% YoYOperating Income
-$84.42M
FY 2025 · Annual
Net Income
-$79.62M
FY 2025 · Annual
Income Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 16.15M | 13.86M |
| Cost of Revenue | 0 | 0 | 0 | 475K | 2.39M |
| Gross Profit | 0 | 0 | 0 | 15.67M | 11.47M |
| Gross Margin | — | — | — | 97.1% | 82.8% |
| Research & Development | 51.05M | 86.13M | 49.59M | 58.75M | 73.7M |
| Selling, General & Admin | 18.66M | 37.35M | 32.61M | 25.42M | 22.19M |
| Operating Expenses | 69.72M | 123.48M | 82.2M | 105.13M | 95.89M |
| Depreciation & Amortization | 647K | 709K | 1.93M | 2.98M | 4.51M |
| EBITDA | (75.33M) | (120.01M) | (71.86M) | (65.51M) | (73.72M) |
| EBITDA Margin | — | — | — | -405.8% | -532.0% |
| Operating Income | (69.72M) | (123.48M) | (82.2M) | (89.46M) | (84.42M) |
| Operating Margin | — | — | — | -554.1% | -609.2% |
| Interest Income | 23K | 2.76M | 6.63M | 7.04M | 3.61M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (6.26M) | 2.76M | 8.41M | 9.97M | 6.19M |
| Income Before Tax | (75.98M) | (120.72M) | (73.79M) | (79.5M) | (78.24M) |
| Pre-Tax Margin | — | — | — | -492.4% | -564.5% |
| Income Tax Expense | 0 | 0 | 0 | (2.16M) | 1.39M |
| Net Income | (75.98M) | (120.72M) | (73.79M) | (77.33M) | (79.62M) |
| Net Margin | — | — | — | -478.9% | -574.5% |
| EPS (Basic) | (2.53) | (3.57) | (1.85) | (1.32) | (1.28) |
| EPS (Diluted) | (2.53) | (3.57) | (1.85) | (1.32) | (1.28) |
| 32.22M | 33.03M | 39.9M | 58.45M | 62.14M | |
| 32.22M | 33.03M | 39.9M | 58.45M | 62.14M |
PYXS Earnings Waterfall · TTM
NASDAQ:PYXS · Revenue to Net Income
Key Ratios
EPS$-1.31
Gross Margin51.0%
Net Margin-203.7%
P/E Ratio-1.1
P/S Ratio7.7
Analysis
$13.9M of revenue converted into -$81.7M of net income for the selected period. Gross margin is 51.0% and net margin is -203.7%, showing how much revenue survives after costs and taxes. EPS is $-1.31, tying the income statement back to per-share earnings.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 8-K | Current report | Nov 13, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 6, 2026 | |
| 8-K | Current report | Nov 5, 2026 | |
| 10-Q | Quarterly report | Nov 5, 2026 | |
| SC 13G/A | SC 13G/A filing | Nov 3, 2026 |
How much revenue does PYXS generate?
Pyxis Oncology, Inc. (PYXS) reported $13.86M of revenue in fiscal 2025.
Is PYXS profitable?
Pyxis Oncology, Inc. (PYXS) reported -$79.62M of net income, with a net margin of -574.5%.
Continue the stock analysis
Jump to another research area for this company.